Millennium: The Takeda Oncology Company (MLNM)

Oncology Corporate Profile

HQ Location

40 Landsdowne Street
Cambridge, MA 2139

Company Description

Millennium is one of the world's top biopharmaceutical companies that engages in the discovery, development, and commercialization of medicines for cancer, inflammatory bowel, and other inflammatory diseases.

Website: http://www.mlnm.com

Brand Generic Indication
Adcetris®brentuximab vedotinAdcetris® is a CD30-directed antibody-drug conjugate indicated for:

• The treatment of patients with Hodgkin lymphoma after failure of autologous stem cell transplant (ASCT) or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not ASCT candidates.

• The treatment of patients with systemic anaplastic large cell lymphoma after failure of at least one prior multi-agent chemotherapy regimen.

These indications are based on response rate. There are no data available demonstrating improvement in patient reported outcomes or survival with Adcetris®.
Alunbrig™brigatinibAlunbrig™ is a kinase inhibitor indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib. This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
Ninlaro®ixazomibNinlaro® is a proteasome inhibitor indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy
Velcade®bortezomibVelcade® is a proteasome inhibitor indicated for treatment of patients with multiple myeloma; treatment of patients with mantle cell lymphoma who have been untreated or received at least 1 prior therapy.

View additional information on commercial products here »

  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
Mepact® / mifamurtidemacrophage activatorOsteosarcomaIII
Velcade® / bortezomibproteasome inhibitor2nd line follicular Non-Hodgkin's Lymphoma (f-NHL)III
Velcade® / bortezomibproteasome inhibitorMantle Cell Lymphoma (MCL)III
Velcade® / bortezomibproteasome inhibitorPreviously untreated Multiple MyelomaIII
motesanib diphosphate / AMG 706VEGFR1-3, PDGFR, c-Kit inhibitor (oral)1st line metastatic Breast cancerIISeattle Genetics
alisertib / MLN8237seceltive Inhibitor of Aurora A kinase2nd line metastatic B-cell and T-cell non-Hodgkin lymphoma (NHL)II
tandutinib / MLN518Flt-3, PDGFR and c-KIT inhibitor (oral)Acute Myelogenous Leukemia (AML)II
TAK-228mTORC1/2 inhibitorBreast cancerII
MLN0128dual mTORC1 and mTORC2 inhibitorBreast cancerII
tandutinib / MLN518Flt-3, PDGFR and c-KIT inhibitor (oral)Glioblastoma Multiforme (GBM)II
CBP501serine/threonine kinase inhibitorNon Small Cell Lung Cancer (NSCLC)IICanBas Co.
IDM-2101immunotherapy (synthetic vaccine)Non Small Cell Lung Cancer (NSCLC)II
alisertib / MLN8237aurora A kinase inhibitor (oral)Ovarian cancerII
TAK-385GnRH antagonist (oral)Prostate cancerII
TAK-228mTORC1/2 inhibitorRenal cell carcinoma (RCC)II
alisertib / MLN8237aurora A kinase inhibitor (oral)Small Cell Lung Cancer (SCLC)II
Velcade® / bortezomibproteasome inhibitorDiffuse large B-cell Lymphoma (DLBCL)II
TAK-924NEDD 8 activating enzyme inhibitorAcute Myelogenous Leukemia (AML)I
tabalumab / LY2127399 (+ bortezomib)BAFF antibodyGastric cancerILilly
ixazomib / MLN9708proteasome inhibitor (oral/injection)Multiple MyelomaI
INK128dual mTORC1/2 inhibitorMultiple MyelomaI
TAK-733MEK inhibitorVarious cancer typesINULl
MLN4924NAE inhibitorVarious cancer typesI
INK1117PI3k inhibitorVarious cancer typesI
INK128 (+ paclitaxel)mTORC1/2 inhibitorVarious cancer typesI
TAK-659spleen tyrosine kinase (SYK) inhibitorVarious cancer typesINULl
TAK-701anti-hepatocyte growth factor (HGF) monoclonal antibodyVarious cancer typesI
MLN8054aurora A kinase inhibitorVarious cancer typesI
INK128mTORC1/2 inhibitorVarious cancer typesI
MLN7243UAE inhibitorVarious cancer typesI
MLN0128dual mTORC1 and mTORC2 inhibitorVarious cancer typesI
MLN0264antibody drug conjugates (ADC)Various cancer typesI
MLN2480Pan-Raf kinase inhibitorVarious cancer typesI
MLN1117P13K alpha inibitorVarious cancer typesI
INK128mTORC1/2 inhibitorWaldenstrom macroglobulinemia (WM)I

View additional information on product candidates here »

Source: Sources: http://www.mlnm.com

Recent News Headlines

Mount Sinai’s Discovery of an Epigenetic Regulator of Tumorigenesis Suggests New Strategies Against Lethal Forms of Breast Cancer

6/27/2016 11:04 am

(Mount Sinai) June 23, 2016 - Mount Sinai scientists have identified a previously unknown mechanism by which a protein called CBX8 promotes tumor growth in the most lethal forms of breast cancer.

Parkinson’s: A Progressive, Incurable Disease

6/5/2016 07:00 pm

(New York Times) June 4, 2016 - What are the likely causes of the disorder that afflicted Muhammad Ali for decades? And what’s the prognosis for those with a Parkinson’s diagnosis?

CancerCare® Announces First-Ever Acute Myeloid Leukemia Awareness Month in June

5/25/2016 11:03 am

(CancerCare) May 25, 2016 - CancerCare today announced the launch of the first-ever Acute Myeloid Leukemia Awareness Month to be held in June. The goal of the campaign is to put a spotlight on the disease, a rare and difficult-to-treat blood cancer that typically affects older adults.

Valeant Said to Weigh Sale of Skin, Cancer Drugs to Cut Debt

5/18/2016 12:01 pm

(Bloomberg) May 18, 2016 - Valeant Pharmaceuticals International Inc. is exploring the sale of some of its smaller cosmetic and pharmaceutical assets, according to people familiar with the matter, as the Canadian drugmaker scrambles to raise cash and reduce debt.

New Research Detects Kidney Cancer

5/17/2016 11:05 am

(Chalmers University Of Technology [Gothenburg, Sweden]) May 13, 2016 - New research shows the possibility to detect kidney cancer with a simple blood or urine test. This paves the way for screening, and might help to determine which treatment works. The study is now published in Cell Reports.

How A Cancer Drug Has Saved People From Going Blind

5/6/2016 12:01 pm

(NPR/Shots blog) May 6, 2016 - This week, a large study of Avastin and Lucentis, the Comparison of AMD Treatment Trials (CATT), came out with data that looked at how people did after five years of treatment.

Bayer Says Its Drug Extends Lives Of Liver Cancer Patients

5/4/2016 01:00 pm

(Reuters) May 4, 2016 - Bayer AG said on Thursday its Regorafenib cancer treatment drug helped extend the lives of liver cancer sufferers according to the results of a Phase III clinical trial.

New HPV Vaccine Could Curb Cervical Cancers And Health Costs If Adopted Widely

4/19/2016 02:01 pm

(Yale News) Apr 18, 2016 - A Yale-led study finds that a new vaccine for human papillomavirus (HPV) would significantly reduce both cervical cancer incidence and healthcare costs if states coordinated policies to improve coverage.

FDA to Review Bristol-Myers’s Opdivo for Hodgkin Lymphoma

4/14/2016 12:03 pm

(Morningstar/Dow Jones Newswires) Apr 14, 2016 - The U.S. Food and Drug Administration has accepted Bristol-Myers Squibb Co.’s supplemental biologics license application to expand the use of its cancer drug Opdivo to patients who are facing difficult-to-treat variations of Hodgkin lymphoma, the pharmaceutical company said Thursday.

Specific Gene In The Tumor Determines The Effectiveness Of Cancer Treatment

4/14/2016 11:01 am

(MedUni Vienna [Austria]) Apr 14, 2016 - Mutations in the TP53 gene can have harmful consequences.

Gene Tests May Help Predict Outcomes in Advanced Ovarian Cancer

3/21/2016 11:02 am

(Drugs.com/HealthDay News) Mar 19, 2016 - A special genetic test might help gauge outcomes for women diagnosed with ovarian cancer, a new study suggests.

How Medicare Drug Plans Hope To Follow Private Sector Lead

3/18/2016 10:02 am

(Kaiser Health News) Mar 18, 2016 - Aetna and Cigna inked deals in early February with drugmaker Novartis that offer the insurers rebates tied to how well a pricey new heart failure drug works to cut hospitalizations and deaths.

Allergan Confirms Generic Abraxane® Patent Challenge

3/17/2016 11:03 am

(PharmPro.com) Mar 17, 2016 - Allergan plc confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the FDA seeking approval to market Paclitaxel Protein-Bound Particles for Injectable Suspension, 100 mg/vial.

'Intriguing': Do Blood Cells Herald Breast Cancer Return?

3/11/2016 11:01 am

(Medscape Medical News) Mar 10, 2016 - White cell counts may be a prognostic tool in early-stage breast cancer, according to new research published online March 7 in ESMO Open.

Cynvenio Launches Breast Cancer Clinical Trial

3/4/2016 12:01 pm

(San Fernando Valley Business Journal) Mar 3, 2016 - Cynvenio Biosystems Inc. launched a clinical trial Thursday that utilizes the company’s non-invasive liquid biopsy platform to monitor and detect early signs of metastasis in women diagnosed with triple negative breast cancer.

Pediatric Oncology Working Group Publishes Framework on Allocating Chemotherapy and Supportive Care Drugs During a Drug Shortage

2/1/2016 06:05 am

(ASCO in Action) Jan 29, 2016 - On January 29, a pediatric oncology working group released an ethical framework on allocating chemotherapy and supportive care drugs to pediatric cancer patients during a drug shortage.

Deficiencies at Theranos 'Pose Immediate Jeopardy to Patient Health'

1/28/2016 12:04 pm

(Washington Post/Wonkblog) Jan 27, 2016 - Theranos, the high-profile Silicon Valley company that promised to revolutionize blood testing, was warned by federal regulators this week that its Newark, Calif. laboratory has "deficient practices" that "pose immediate jeopardy to patient health and safety," according to a letter sent to the company this week.

Obama Creates New Cancer Task Force, Blessing Biden's Effort

1/28/2016 12:01 pm

(ABC News/Associated Press) Jan 28, 2016 - President Barack Obama created a new federal task force Thursday to accelerate cancer research, putting Vice President Joe Biden in charge of the drive to streamline government efforts toward a cure.

Risk Factor for Early Death in Cancer Patients: Bankruptcy

1/28/2016 12:01 pm

(Medscape Medical News) Jan 28, 2016 - Severe financial distress requiring bankruptcy protection after a cancer diagnosis appears to be a risk factor for early mortality, according to a first-of-its kind finding.

FDA To Take Another Look At Essure Contraceptive Device After Health Complaints

7/15/2015 12:02 pm

(NPR/Shots blog) July 14, 2015 - The FDA scheduled a public advisory meeting of its Obstetrics and Gynecology Devices Panel on Sept. 24 that will bring together experts, physicians and patient and industry advocates to review the data and hear public comments from women.

Siemens and BioNTech Cooperate on Production of Personalized Cancer Vaccines

6/25/2015 12:03 pm

(Siemens) June 25, 2015 - Siemens and BioNTech AG, a fully integrated biotechnology company developing truly personalized cancer immunotherapies, have entered into a strategic collaboration.

Updated Data Showed Roche’s Investigational Combination of Cobimetinib and Zelboraf (vemurafenib) Helps People with Advanced Melanoma Live for a Year Without Their Disease Worsening

5/30/2015 06:02 pm

(Roche) May 30, 2015 - Phase III coBRIM study demonstrated a median progression-free survival of 12.3 months with cobimetinib plus Zelboraf; additional data from Phase Ib BRIM7 study showed 61 percent of people who had not been previously treated with a BRAF inhibitor were alive after two years.

Attend Free ASCO Webinar on Medicare Oncology Payment Model

4/22/2015 11:04 am

(ASCO in Action) Apr 21, 2015 - ASCO will hold a free webinar on the Center for Medicare and Medicaid Innovation's (CMMI) Oncology Care Model (OCM) on Tuesday, April 28, 2015 at 4:00 p.m. EDT.

FDA Staff Backs Medicines Co's Once-rejected Blood Clot Preventer

4/13/2015 12:02 pm

(Reuters) Apr 13, 2015 - An intravenous blood clot preventer developed by The Medicines Co should be approved by the U.S. Food and Drug Administration, FDA staff reviewers concluded.

Lisa Bonchek Adams, Who Wrote About Her Cancer, Dies

3/10/2015 11:05 am

(Time) Mar 7, 2015 - Lisa Bonchek Adams, a prominent online writer who inspired and provoked readers with her extensive writing on her experience with cancer, died Friday evening.